期刊
AIDS
卷 26, 期 2, 页码 185-192出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0b013e32834e9d7d
关键词
antiretroviral therapy; HIV-1 drug resistance; medication adherence; minority variants; virologic failure
资金
- Bristol-Myers Squibb
- Pfizer
- Merck
- Roche Diagnostics
- IrsiCaixa AIDS Research Institute
- Lluita contra la SIDA Foundation
- ViiV Healthcare
- Siemens
- Boehringer Ingelheim
- Gilead
- Abbott
- ViiV
- Stanford University
- Avexa
- Boehringer-Ingelheim
- GlaxoSmithKline
- Oncolys
- Roche
- Tobira
- Vertex
- ViroStatistics
- Clinical Investigator Training Program
- Harvard/MIT Health Sciences and Technology - Beth Israel Deaconess Medical Center
- Pfizer Inc.
- Merck Co.
- CHAIN
- Collaborative HIV
- Anti-HIV Drug Resistance Network [223131]
- European Commission
- NIH (Statistical and Data Management Center of the AIDS Clinical Trials Group) [U01 AI068634]
- Harvard University CFAR [P30 AI060354]
- VA
- NIH [U01 AI042170, U01 AI 068636, K24 RR016482]
- ACTG
Objectives: To evaluate the risk of virologic failure conferred by suboptimal adherence to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and minority NNRTI resistance mutations. Design: Pooled analysis of the risk of virologic failure conferred by minority NNRTI resistance mutations and NNRTI adherence from three studies of treatment-naive individuals initiating an NNRTI-based regimen. Methods: Participants from each study were categorized into both adherence quartiles (Q1-Q4) and four strata: at least 95%, 80-94%, 60-79%, and below 60%. Weighted Cox proportional hazard models were used to estimate the risk of virologic failure. Results: The majority of participants (N = 768) had high measured adherence, but those in the lowest adherence quartile had the highest proportion of participants with virologic failure and the risk of virologic failure increased step-wise with adherence below 95%. Detection of minority NNRTI drug resistance mutations increased the proportion of participants with virologic failure across adherence quartiles (Cochran-Mantel-Haenszel P < 0.001) and adherence strata [Cochran-Mantel-Haenszel P < 0.001; < 60% adherence, hazard ratio 1.7 (1.1-2.7), P = 0.02; 60-79% adherence, hazard ratio 1.2 (0.5-3.2), P = 0.67; 80-94% adherence, hazard ratio 2.5 (0.98-6.3), P = 0.06; >= 95% adherence, hazard ratio 3.6 (2.3-5.6), P < 0.001]. On multivariate analysis, the effect of minority variants was also most prominent at higher levels of medication adherence. Conclusions: The presence of minority NNRTI resistance mutations and NNRTI adherence were found to be independent predictors of virologic failure, but also modify each other's effects on virologic failure. In addition to the focus on medication adherence counseling, ultrasensitive HIV-1 drug resistance assays could play a role in optimizing the success rates of first-line antiretroviral therapy. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据